16 March 2016 - NICE has today issued draft guidance not recommending talimogene laherparepvec (Imlygic, Amgen) as an option for people with melanoma that has spread and can’t be surgically removed.

For more details, go to: https://www.nice.org.uk/news/press-and-media/nice-consults-on-‘no’-recommendation-for-skin-cancer-drug-talimogene-laherparepvec